Published: Monday, June 16, 2025 · 1:45 AM | Updated: Monday, June 16, 2025 · 1:45 AM
📊 282 views
Innovent Biologics (IVBXF, Financial) has commenced the GLORY-OSA Phase 3 clinical trial, dosing its first participant. The trial focuses on mazdutide, a dual receptor agonist targeting glucagon and glucagon-like peptide-1, in Chinese patients suffering from moderate-to-severe obstructive sleep apnea and obesity. This marks the seventh Phase 3 study for mazdutide in China, emphasizing its potential role in treating obesity and related metabolic disorders. The goal is to acquire robust evidence to support clinical applications of this treatment.
MORE IN INSIDE INVESTMENT NEWS
PepsiCo Earnings: A Deeper Dive into North American Consumer Shifts
Published: Thursday, July 9, 2026 · 10:36 AM
Nike stock: A Portfolio Warning After Disappointing Quarter
Published: Tuesday, June 30, 2026 · 11:47 PM
